Zobrazeno 1 - 10
of 73
pro vyhledávání: '"John Gatfield"'
Autor:
Katarina Zmajkovicova, Yasmina Bauer, Katalin Menyhart, Marie Schnoebelen, Diego Freti, Maxime Boucher, Bérengère Renault, Rolf Studer, Magdalena Birker-Robaczewska, Axel Klenk, Oliver Nayler, John Gatfield
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228195 (2020)
Tissue fibrosis is a pathological condition characterized by uncontrolled fibroblast activation that ultimately leads to organ failure. The TGFβ1 pathway, one of the major players in establishment of the disease phenotype, is dependent on the transc
Externí odkaz:
https://doaj.org/article/282eb950f8d8439b83951dce674b541e
Autor:
Patrick Sieber, Anny Schäfer, Raphael Lieberherr, François Le Goff, Manuel Stritt, Richard W D Welford, John Gatfield, Oliver Peter, Oliver Nayler, Urs Lüthi
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207872 (2018)
Pathological features of pulmonary fibrosis include accumulation of myofibroblasts and increased extracellular matrix (ECM) deposition in lung tissue. Contractile α-smooth muscle actin (α-SMA)-expressing myofibroblasts that produce and secrete ECM
Externí odkaz:
https://doaj.org/article/015179c2a49047e79610cca7f51ef289
Autor:
Olivier Bezençon, Thomas Pfeifer, Johannes Mosbacher, Isabelle Reymond, Eric A. Ertel, Ruben de Kanter, Bruno Capeleto, Elvire Fournier, Markus Rey, Luca Moccia, Michael Toeroek-Schafroth, René Roscher, Richard Moon, John Gatfield, Melanie Kessler, Romain Siegrist, Bibia Heidmann, Davide Pozzi, Simon Stamm, Luboš Remeň, Sylvia Richard, Lloyd Simons, Rick Gaston, Dennis Downing, Corinna Grisostomi, Catherine Roch, Benno Schindelholz
Publikováno v:
CHIMIA, Vol 71, Iss 10 (2017)
We describe the discovery and optimization of new, brain-penetrant T-type calcium channel blockers. We present optimized compounds with excellent efficacy in a rodent model of generalized absence-like epilepsy. Along the fine optimization of a chemic
Externí odkaz:
https://doaj.org/article/77760779eafd425e854518b6109e1f36
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107809 (2014)
The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ET(A) receptor. Th
Externí odkaz:
https://doaj.org/article/61b5245ae4f64690b2cf876aaefcc702
Autor:
Markus Rey, Patrick Hess, Martine Clozel, Stéphane Delahaye, John Gatfield, Oliver Nayler, Beat Steiner
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74285 (2013)
Ponesimod, a selective S1P1 receptor modulator, reduces the blood lymphocyte count in all tested species by preventing egress of T and B cells from thymus and peripheral lymphoid organs. In addition, ponesimod transiently affects heart rate and atrio
Externí odkaz:
https://doaj.org/article/d79ad88e62a94ce89ceedd137f337bd6
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47662 (2012)
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proli
Externí odkaz:
https://doaj.org/article/503a90c34503419ebb9919218d92ae26
Autor:
Alexander Treiber, Stephane Delahaye, Aude Weigel, Päivi Aeänismaa, John Gatfield, Swen Seeland
Publikováno v:
Xenobiotica. :1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2930e1c9e76ec63d4baf47c3aa3dfeda
https://doi.org/10.1080/00498254.2023.2183159
https://doi.org/10.1080/00498254.2023.2183159
Autor:
John Gatfield, Catherine Roch, Thierry Sifferlen, Jodi T. Williams, Alexander Treiber, Christoph Boss, Martin Bolli, Christine Brotschi, Bibia Heidmann, Francois Jenck
Publikováno v:
ChemMedChem. 14:1257-1270
The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline our optimization efforts toward a novel DORA. We st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b115f7c0f955cf770604ab0fdaa3d44
https://doi.org/10.1002/cmdc.201900242
https://doi.org/10.1002/cmdc.201900242
The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ
Autor:
John Gatfield, Marie Schnoebelen, Katalin Menyhart, Katarina Zmajkovicova, Bérengère Renault, Matthias Bolinger, Rolf Studer, Yasmina Bauer, Oliver Nayler
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology. 60:578-591
Idiopathic pulmonary fibrosis is a life-threatening progressive disease characterized by loss of alveolar epithelial cells, inflammation, and aberrant fibroblast activation. The two currently approved therapies do not halt or reverse tissue remodelin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46ef65a26b3065dc3249ab5a6c3a01b3
https://doi.org/10.1165/rcmb.2018-0142oc
https://doi.org/10.1165/rcmb.2018-0142oc
Autor:
Markus von Raumer, Bibia Heidmann, Christoph Boss, John Gatfield, Catherine Roch, Jodi T. Williams, Christine Brotschi, Alexander Treiber, Thierry Sifferlen, Gunther Schmidt
Publikováno v:
ChemMedChem. 15(23)
Since its discovery in 1998, the orexin system has been of interest to the research community as a potential therapeutic target for the treatment of sleep/wake disorders, stress and anxiety disorders, addiction or eating disorders. It consists of two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a288d5cb5ef111945479c378d0102354
https://pubmed.ncbi.nlm.nih.gov/32937014
https://pubmed.ncbi.nlm.nih.gov/32937014